Menu
ncarol.com
  • Home
  • Books
  • Book Release
  • Health
  • Business
  • Real Estate
  • Arts
  • Music
  • Education
ncarol.com

The ROS1ders Issue RFA for $75K ROS1+ Cancer Innovation Award
ncarol.com/10256312

Trending...
  • Sexually Abused in a Psychiatric Hospital or Psychiatrist's or Psychologist's Office? CCHR Urges Survivors to Reach Out to It
  • Healthcare Leaders Publish New Integrated Behavioral Healthcare Guide, Led by Doctors of Behavioral Health
  • Leicester UK Manufacturer Tabletop Tyrant Secures Flawless 100% Customer Satisfaction Rating Across 5,800+ Orders
Patient-founded nonprofit seeks to stimulate innovative research to improve outcomes for patients with ROS1+ cancers.

SACRAMENTO, Calif. - ncarol.com -- The ROS1ders is pleased to issue their 2024 Request for Application (RFA) to study ROS1-positive (ROS1+) cancer. The RFA is open to investigators who hold a doctorate degree and a faculty appointment at an academic or non-profit research institution anywhere in the world.

"While oral targeted therapies are approved to treat ROS1+ cancer, the drugs don't work for everyone, and they eventually stop working. We are committed to investing in research to improve patient outcomes," says Janet Freeman-Daily, MS, Engr, co-founder and president of The ROS1ders.

The ROS1+ Cancer Innovation Award aims to fund high-risk, high-reward projects focused on ROS1+ cancers. The one-year $75,000 seed grant can be used for pre-clinical, translational, or clinical research.

"Seed grants allow for the generation of initial data to support larger research endeavors," said D. Ross Camidge, MD, PhD, Professor of Medicine/Oncology at the University of Colorado and a member of The ROS1ders Scientific Advisory Board. "While some seeds fail, others grow into mighty trees - they can be the seeds of real breakthroughs."

More on ncarol.com
  • IGH Naturals Announces Peer-Reviewed HuMOLYTE® Study Published in Frontiers in Nutrition
  • Allstream Energy Partners Expands AI-Optimized Website Development Division to Meet Growing Demand in GEO / AEO Services
  • America's Workforce Solution Named an OpenAI SMB Channel Partner, Bringing Enterprise-Grade AI to Main Street
  • Data Tiles Introduces the Decision-Driven Enterprise to North America
  • FitTrace Sync 1.11 Brings Apple Health and Google Health Connect Integration Into Its Mobile App

The award program uses a two-step application process. The deadline for a letter of intent is May 3, 2024. Those invited to submit a full application must provide it by August 4, 2024. For more information, visit https://theros1ders.org/seed-grant-program.

About the ROS1ders

Founded by patients in 2015 and incorporated in 2019, The ROS1ders is the largest global group of patients and family members living with ROS1+ cancer. It seeks to improve outcomes for all ROS1+ cancers through community, education, and research. Membership in their private Facebook group exceeds 1200 people from over 30 countries. The nonprofit is internationally recognized in the oncology and patient advocacy communities as experts in their disease. Its resources include a medically-vetted website and collaboration with international ROS1+ clinicians, researchers and industry. Please visit theros1ders.org to learn more.

More on ncarol.com
  • Disruptor Creations Pioneers New MicroAdventure Series with TravelSpike
  • eCopier Solutions Surpasses 3,000 Five-Star Google Reviews and Maintains Perfect Five-Star Rating
  • Creative Investment Research Welcomes Supreme Court Decision Protecting Federal Reserve Independence While Calling for Continued Accountability
  • New from Regal House Publishing, The Reel Life of Zara Kegg: Love, grief, Godzilla, odd beach winter
  • Ascent Solar Technologies (N A S D A Q: ASTI): Positioned at the Intersection of the New Space Economy, Defense Innovation and Next-Generation Energy

About ROS1+ Cancer
  • ROS1+ cancer is relatively rare, occurring in just 1-2% of non-small cell lung cancer (NSCLC). The incidence is thought to be similar in other types of cancer.
  • Biomarker testing for ROS1 fusions is recommended in guidelines for non-small cell lung cancer (NSCLC), but for few other cancers.
  • Patients are typically younger than the average NSCLC patient, have adenocarcinoma, and have no smoking history (a smoking history should not exclude patients from biomarker testing or targeted therapies).
  • Oral targeted therapies are the recommended first-line treatment for metastatic ROS1+NSCLC and have increased the survival of patients by years. However, these drugs eventually stop working due to acquired resistance. The mechanisms of resistance are not well understood.


Contact
Janet Freeman-Daily
***@theros1ders.org


Source: The ROS1ders, Inc.
Filed Under: Health

Show All News | Disclaimer | Report Violation

0 Comments
1000 characters max.

Latest on ncarol.com
  • Boston Industrial Solutions Introduces High-Performance Primer for Bonding Liquid Silicone to Epoxy
  • New Comprehensive Guide Unveils the Ultimate Masterlist of Government-Approved Business Funding
  • Healthcare Leaders Publish New Integrated Behavioral Healthcare Guide, Led by Doctors of Behavioral Health
  • Marketing Company Helps Local Businesses Stop Renting Leads and Start Building A Permanent System
  • Verbica Challenges Panetta to a Televised Debate on the Issues
  • Salt Lake City Families Turn to Private Autopsy Services for Faster Answers After Unexpected Loss
  • K2 Integrity's U.S. and EMEA Teams Again Recognized in Chambers and Partners 2026 Guides
  • Connecta Satellite Solutions Ready to Support Emergency Communications Following the Venezuela Earthquake
  • Rare 1933 Harold Weston painting will be auctioned to benefit the Keene Valley Library
  • $20 Million Revenue Target, Accelerating Growth, 7% Of Outstanding Shares Retired, Clear Path Toward Profitability: VSee Health, Inc N A S D A Q: VSEE
  • HomeCentris Home Health Achieves 5-Star CMS Rating
  • Adsoptia Launches AI-Powered Optimization Platform for a New Era of Autonomous Marketing Decisions
  • Heritage at Manalapan Announces New Incentive: Included Finished Basement on Select Homesites
  • Leicester UK Manufacturer Tabletop Tyrant Secures Flawless 100% Customer Satisfaction Rating Across 5,800+ Orders
  • The Calida Group Announces Promotion of Joshua Nelson to President, Advancing Next Phase of National Growth
  • Cango Mobility x Hikvision Announce Strategic Partnership
  • HomeCentris Healthcare Signs Definitive Agreement to Acquire S&K Holdings, Expanding Mid Atlantic Platform
  • Nayarit Strengthens Its Position as a Global Surf Destination; Sayulita to Become Mexico's First Official Surf City
  • Custom Cushions and Sewing Solutions Available in Cleveland County and Surrounding Areas
  • Century Fasteners de Mexico Exhibiting at 2026 Farnborough International Airshow
_catLbl0 _catLbl1

Popular on ncarol.com

  • Kevin Francis Design Introduces CHROMA, a Collection of Saturated Solid Color Wool Rugs - 459
  • Agape Leadership Academy Opens Nationwide Enrollment — State ESA Scholarships Cover Full Tuition for Families in 7 States - 126
  • Boston Industrial Solutions Introduces New Natron® 310 Hyper White UV Ink for Enhanced Printing Performance - 111
  • Revenue Optics Expands Its Private Equity Practice as Sponsors Move Inside Sales to the Center of Distribution Value Creation - 106
  • UK Financial Ltd Completes One Of The Most Extensive CoinMarketCap Supply Verification Packages For Maya Preferred PRA (MPRA)
  • Psychiatric Hospitals Fail to Warn Electroshock Patients of FDA-Cited Risks in Estimated $7 Billion Industry
  • Nevada Boxing Hall of Fame Announces 14th Annual Induction Gala Weekend Honoring Classes of 2025 and 2026
  • AI Is Making It Easier for API-First Platforms to Connect, Partner, Reach Customers, and Grow Revenue Faster
  • Exclusive Red-Carpet Screening of High-Stakes Indie Thriller "Queen City: The Hornet's Nest" Coming to North Carolina on June 20th
  • A New Pulse for Cardiac Care in Baltimore: St. Elizabeth Rehab & Nursing Welcomes Dr. Hakim Uqdah and Expands Advanced Heart Program

Similar on ncarol.com

  • Contracting Resources Group Recognized by The Daily Record as a 2026 In the Lead: Best Women-Owned Businesses Honoree
  • IGH Naturals Announces Peer-Reviewed HuMOLYTE® Study Published in Frontiers in Nutrition
  • FitTrace Sync 1.11 Brings Apple Health and Google Health Connect Integration Into Its Mobile App
  • Triple-Digit Growth, Stock Market Upgrade plus a Rapidly Expanding Specialty Healthcare Platform: Cardiff Lexington Corporation (Stock Symbol: CDIX)
  • AI-Powered Neuropsychiatry, FDA Regulatory Momentum, Commercial Ketamine Launch Position NRx Pharmaceuticals for Potential Breakout Growth in 2026
  • Sexually Abused in a Psychiatric Hospital or Psychiatrist's or Psychologist's Office? CCHR Urges Survivors to Reach Out to It
  • Healthcare Leaders Publish New Integrated Behavioral Healthcare Guide, Led by Doctors of Behavioral Health
  • Salt Lake City Families Turn to Private Autopsy Services for Faster Answers After Unexpected Loss
  • $20 Million Revenue Target, Accelerating Growth, 7% Of Outstanding Shares Retired, Clear Path Toward Profitability: VSee Health, Inc N A S D A Q: VSEE
  • HomeCentris Home Health Achieves 5-Star CMS Rating
Copyright © 2026 ncarol.com | Contact Us | Privacy Policy | Terms of Service | Contribute